Yahoo Finance Should You Buy ImmunoGen (IMGN) After Golden Cross?
After reaching an important support level, ImmunoGen, Inc. (IMGN) could be a good stock pick from a technical perspective. IMGN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typically, a golden cross involves the 50-day and the 200-day moving averages, since bigger time periods tend to form stronger breakouts.
There are three stages to a golden cross. First, there must be a downtrend in a stock's price that eventually bottoms out. Then, the stock's shorter moving average crosses over its longer moving average, triggering a positive trend reversal. The third stage is when a stock continues the upward momentum to higher prices.
This kind of chart pattern is the opposite of a death cross, which is a technical event that suggests future bearish price movement.
IMGN could be on the verge of a breakout after moving 250.4% higher over the last four weeks. Plus, the company is currently a #2 (Buy) on the Zacks Rank.
Looking at IMGN's earnings expectations, investors will be even more convinced of the bullish uptrend. For the current quarter, there have been 8 changes higher compared to none lower over the past 60 days, and the Zacks Consensus Estimate has moved up as well.
With a winning combination of earnings estimate revisions and hitting a key technical level, investors should keep their eye on IMGN for more gains in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report
